個人化醫療生物標記市場規模、佔有率和成長分析：按生物標記類型、產品/服務、技術、應用、臨床用途、最終用戶和地區分類－2026-2033年產業預測

2024 年全球個人化醫療生物標記市場價值為 279 億美元，預計到 2033 年將從 2025 年的 318.9 億美元成長到 929 億美元，預測期（2026-2033 年）的複合年成長率為 14.3%。

全球個人化醫療生物標記市場正受到分子診斷、巨量資料分析和標靶治療融合的推動，醫療保健正從團體策略轉向個人化治療。這些生物標記涵蓋基因組學、蛋白質組學和代謝組學，能夠在提高療效的同時，最大限度地減少不利事件和成本。從基礎的單基因檢測到複雜的多參數檢測和腫瘤伴隨診斷，監管部門的核准和保險公司的認可正在推動這一發展，促進其廣泛應用。定序成本的降低和分析能力的提升正在加速市場成長，使企業能夠擴展基因組分析和液態生物檢體服務。此外，有利的法規和政策正在促進伴隨診斷的使用，從而為精準腫瘤學和數位生物標記整合創造了機會。同時，人工智慧技術正在簡化生物標記的發現和患者分層流程，提高臨床應用效率。

全球個人化醫療生物標記市場促進因素

全球個人化醫療生物標記市場正受到基因測序技術、生物資訊解決方案以及多體學方法整合的顯著推動。這些進步增強了有效個人化醫療生物標記的識別，有助於精準的患者分層，並實現標靶治療的選擇。檢測靈敏度和特異性的提高，以及更有效率的檢體處理，增強了臨床醫生和相關人員對生物標記實用化的信心，加速了其在各個治療領域的應用。這種不斷成長的勢頭推動了對生物標記發現和診斷技術研發的投資增加，促進了行業相關人員和醫療服務提供者之間的合作，最終為創新型個人化診斷創造了市場擴張和新的機會。

全球個人化醫療生物標記市場面臨的限制因素

全球個人化醫療生物標記市場面臨許多挑戰，這些挑戰源於與生物標記檢驗、臨床證據和診斷設備分類相關的複雜且不斷變化的監管要求。這些複雜的法規為開發商和投資者帶來了不確定性，阻礙了商業化進程。不同司法管轄區之間的期望差異，加上漫長的審查週期，使得市場准入更加複雜，需要耗費大量時間和資源進行臨床檢驗和監管申報。這種環境可能會阻礙中小企業在創新生物標記開發方面的努力，限制策略合作，並將重點轉移到更安全但創新性較低的專案上，最終阻礙個人化診斷的廣泛應用，並減緩市場成長。

全球個人化醫療生物標記市場趨勢

全球個人化醫療生物標記市場正日益受到人工智慧驅動的生物標記發現技術進步的影響。機器學習與先進計算建模的融合，正透過利用多樣化的臨床和分子資料集，革新生物標記的識別和優先排序方式。這種方法加速了複雜生物學模式的解析，增強了假設生成能力，並縮短了發現時間。隨著相關人員接受更高的模型透明度和可互通的數據標準，臨床醫生、研究人員和行業相關人員之間的合作得到加強，轉化研究流程也得到簡化。此外，預測分析技術的進步正在支持更複雜的生物標記組合、個人化患者分層和標靶治療的開發，同時也正在應對與數據品質和可解釋性相關的挑戰。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球個人化醫療生物標記市場規模：按生物標記類型分類

• 基因生物標記
• 蛋白質體學生物標記
• 代謝體學物標誌物
• 轉錄組生物標記
• 表觀遺傳生物標記
• 免疫學生物標記
• 其他

全球個人化醫療生物標記市場規模：按產品/服務分類

• 消耗品
  • 檢測試劑盒
  • 試劑
  • 面板和陣列
• 裝置
  • 定序設備
  • PCR系統
  • 質譜系統
  • 生物資訊平台
• 服務
  • 生物標記發現服務
  • 驗證服務
  • 伴隨診斷開發服務
  • 數據分析與解釋服務

全球個人化醫療生物標記市場規模：按技術分類

• 次世代定序（NGS）
• 聚合酵素鏈鎖反應（PCR）
• 免疫檢測
• 質譜分析
• 微陣列技術
• 原位雜合反應
• 生物資訊學和人工智慧分析
• 其他

全球個人化醫療生物標記市場規模：按應用領域分類

• 腫瘤學
• 神經病學
• 循環系統
• 感染疾病
• 免疫學與自體免疫疾病
• 罕見疾病
• 代謝性疾病
• 其他

全球個人化醫療生物標記市場規模：按臨床應用價值分類

• 診斷生物標記
• 預後生物標記
• 預測性生物標記
• 動態物標誌物
• 監測生物標記
• 安全生物標記

全球個人化醫療生物標記市場規模：按最終用戶分類

• 製藥和生物技術公司
• 診斷檢查室
• 醫院和診所
• 學術研究機構
• 受託研究機構（CRO）

全球個人化醫療生物標記市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• F. Hoffmann-La Roche Ltd
• Thermo Fisher Scientific Inc.
• QIAGEN NV
• Illumina, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Abbott Laboratories
• Siemens Healthineers AG
• Becton, Dickinson and Company
• Guardant Health, Inc.
• Myriad Genetics, Inc.
• Exact Sciences Corporation
• Foundation Medicine, Inc.
• NeoGenomics Laboratories, Inc.
• Biocartis Group NV
• Pacific Biosciences of California, Inc.
• Natera, Inc.
• Bio-Techne Corporation
• PerkinElmer, Inc.

結論與建議

Global Personalized Medicine Biomarkers Market size was valued at USD 27.9 Billion in 2024 and is poised to grow from USD 31.89 Billion in 2025 to USD 92.9 Billion by 2033, growing at a CAGR of 14.3% during the forecast period (2026-2033).

The global personalized medicine biomarkers market is fueled by the integration of molecular diagnostics, big data analytics, and targeted therapies, shifting care from population strategies to individualized approaches. These biomarkers, comprising genomic, proteomic, and metabolomic indicators, enhance treatment efficacy while minimizing adverse events and costs. The evolution from basic single-gene tests to intricate multi-analyte panels and companion diagnostics for oncology has been bolstered by regulatory acceptance and payer willingness, driving widespread implementation. Reductions in sequencing costs and improved analytical capabilities have catalyzed growth, allowing companies to expand their genomic profiling and liquid biopsy services. Additionally, favorable regulations and reimbursement policies have promoted the use of companion diagnostics, thereby creating opportunities in precision oncology and digital biomarker integration, while AI technologies streamline biomarker discovery and patient stratification, enhancing clinical application efficiency.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Personalized Medicine Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Personalized Medicine Biomarkers Market Segments Analysis

Global personalized medicine biomarkers market is segmented by biomarker type, product & service, technology, application, clinical utility, end user and region. Based on biomarker type, the market is segmented into Genomic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, Transcriptomic Biomarkers, Epigenetic Biomarkers, Immunological Biomarkers and Others. Based on product & service, the market is segmented into Consumables, Instruments and Services. Based on technology, the market is segmented into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunoassays, Mass Spectrometry, Microarray Technology, In Situ Hybridization, Bioinformatics & AI-Based Analytics and Others. Based on application, the market is segmented into Oncology, Neurology, Cardiology, Infectious Diseases, Immunology & Autoimmune Diseases, Rare Diseases, Metabolic Disorders and Others. Based on clinical utility, the market is segmented into Diagnostic Biomarkers, Prognostic Biomarkers, Predictive Biomarkers, Pharmacodynamic Biomarkers, Monitoring Biomarkers and Safety Biomarkers. Based on end user, the market is segmented into Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories, Hospitals & Clinics, Academic & Research Institutes and Contract Research Organizations (CROs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Personalized Medicine Biomarkers Market

The Global Personalized Medicine Biomarkers market is significantly propelled by advancements in genomic sequencing technologies, bioinformatics solutions, and the integration of multiomics approaches. These improvements enhance the identification of effective personalized medicine biomarkers, facilitating accurate patient stratification and enabling targeted therapy choices. Enhanced assay sensitivity and specificity, coupled with more efficient sample processing, bolster the confidence of clinical and research stakeholders in the practical use of biomarkers, driving their adoption across various therapeutic areas. This growing momentum fosters increased investments in biomarker discovery and diagnostic development, while also encouraging collaborations between industry players and healthcare providers, ultimately expanding the market and creating new opportunities for innovative personalized diagnostics.

Restraints in the Global Personalized Medicine Biomarkers Market

The Global Personalized Medicine Biomarkers market faces significant challenges stemming from complex and continuously changing regulatory requirements related to biomarker validation, clinical evidence, and the classification of diagnostic devices. These intricate regulations create uncertainty for developers and investors, hindering the commercialization process. Variations in expectations across different jurisdictions, coupled with lengthy review periods, demand extensive time and resources for clinical validation and regulatory submissions, complicating market entry. This environment can deter smaller companies from exploring innovative biomarker development, limit strategic partnerships, and redirect focus toward safer, less innovative projects, ultimately impeding the widespread adoption of personalized diagnostics and slowing market growth.

Market Trends of the Global Personalized Medicine Biomarkers Market

The Global Personalized Medicine Biomarkers market is increasingly influenced by advancements in AI-driven biomarker discovery. The integration of machine learning and sophisticated computational modeling is revolutionizing how biomarkers are identified and prioritized by leveraging diverse clinical and molecular datasets. This approach facilitates the uncovering of intricate biological patterns, enhancing hypothesis generation and expediting discovery timelines. As stakeholders embrace improved model transparency and interoperable data standards, collaboration among clinicians, researchers, and industry stakeholders is strengthened, streamlining the translational process. Furthermore, the evolution of predictive analytics supports more refined biomarker panels, individualized patient stratification, and the development of targeted therapies, while addressing challenges related to data quality and interpretability.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Personalized Medicine Biomarkers Market Size by Biomarker Type & CAGR (2026-2033)

• Market Overview
• Genomic Biomarkers
• Proteomic Biomarkers
• Metabolomic Biomarkers
• Transcriptomic Biomarkers
• Epigenetic Biomarkers
• Immunological Biomarkers
• Others

Global Personalized Medicine Biomarkers Market Size by Product & Service & CAGR (2026-2033)

• Market Overview
• Consumables
  • Assay Kits
  • Reagents
  • Panels & Arrays
• Instruments
  • Sequencing Instruments
  • PCR Systems
  • Mass Spectrometry Systems
  • Bioinformatics Platforms
• Services
  • Biomarker Discovery Services
  • Validation Services
  • Companion Diagnostic Development Services
  • Data Analysis & Interpretation Services

Global Personalized Medicine Biomarkers Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Immunoassays
• Mass Spectrometry
• Microarray Technology
• In Situ Hybridization
• Bioinformatics & AI-Based Analytics
• Others

Global Personalized Medicine Biomarkers Market Size by Application & CAGR (2026-2033)

• Market Overview
• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Immunology & Autoimmune Diseases
• Rare Diseases
• Metabolic Disorders
• Others

Global Personalized Medicine Biomarkers Market Size by Clinical Utility & CAGR (2026-2033)

• Market Overview
• Diagnostic Biomarkers
• Prognostic Biomarkers
• Predictive Biomarkers
• Pharmacodynamic Biomarkers
• Monitoring Biomarkers
• Safety Biomarkers

Global Personalized Medicine Biomarkers Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical & Biotechnology Companies
• Diagnostic Laboratories
• Hospitals & Clinics
• Academic & Research Institutes
• Contract Research Organizations (CROs)

Global Personalized Medicine Biomarkers Market Size & CAGR (2026-2033)

• North America (Biomarker Type, Product & Service, Technology, Application, Clinical Utility, End User)
  • US
  • Canada
• Europe (Biomarker Type, Product & Service, Technology, Application, Clinical Utility, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Biomarker Type, Product & Service, Technology, Application, Clinical Utility, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Biomarker Type, Product & Service, Technology, Application, Clinical Utility, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Biomarker Type, Product & Service, Technology, Application, Clinical Utility, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• NeoGenomics Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocartis Group NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacific Biosciences of California, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Techne Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations